Stephan Kanzler

7.8k total citations · 1 hit paper
100 papers, 5.1k citations indexed

About

Stephan Kanzler is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stephan Kanzler has authored 100 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 41 papers in Hepatology and 34 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stephan Kanzler's work include Colorectal Cancer Treatments and Studies (28 papers), Liver Disease Diagnosis and Treatment (24 papers) and Liver Diseases and Immunity (23 papers). Stephan Kanzler is often cited by papers focused on Colorectal Cancer Treatments and Studies (28 papers), Liver Disease Diagnosis and Treatment (24 papers) and Liver Diseases and Immunity (23 papers). Stephan Kanzler collaborates with scholars based in Germany, United States and Switzerland. Stephan Kanzler's co-authors include Peter R. Galle, Ansgar W. Lohse, Johannes Herkel, Markus F. Neurath, Karl‐Hermann Meyer zum Büschenfelde, Guido Gerken, Manfred Blessing, Peter Schirmacher, Andreas Teufel and Ralf Kießlich and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Stephan Kanzler

97 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis

2003 606 citations Ralf Kießlich, Martin Holtmann et al. profile →

Peers

Countries citing papers authored by Stephan Kanzler

Since Specialization

Citations

This map shows the geographic impact of Stephan Kanzler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Kanzler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Kanzler more than expected).

Fields of papers citing papers by Stephan Kanzler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Kanzler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Kanzler. The network helps show where Stephan Kanzler may publish in the future.

Co-authorship network of co-authors of Stephan Kanzler

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Kanzler. A scholar is included among the top collaborators of Stephan Kanzler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Kanzler. Stephan Kanzler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial 2024 ·Oncology Research and Treatment ·(unknown), Thorsten Oliver Goetze, Thomas J. Ettrich, Harald Schmalenberg, Michael Clemens, Rolf Mahlberg, Steffen Heeg, Stephan Kanzler, (unknown), Peter Thuss-Patience, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Claudia Pauligk, Salah‐Eddin Al‐Batran, Sylvie Lorenzen	0
2	Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114) 2024 ·Oncology Research and Treatment ·Kathrin Heinrich, Volker Heinemann, Sebastian Stintzing, Lothar Müller, Thomas J. Ettrich, (unknown), Michael Geißler, Jörg Trojan, Nicolas Moosmann, Gunnar Folprecht, Johannes Schmidt, Stephan Kanzler, Frank Kullmann, (unknown), Jens Werner, Martin K. Angele, (unknown), Swantje Held, Christoph Schulz, (unknown)	1
3	Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial 2024 ·The Lancet. Gastroenterology & hepatology ·Klara Dorman, Stefan Boeck, Karel Caca, Maximilian Reichert, Thomas J. Ettrich, Helmut Oettle, Oliver Waidmann, Dominik Paul Modest, Lothar Müller, Patrick Michl, Stephan Kanzler, Daniel Pink, Anke Reinacher‐Schick, Michael Geißler, (unknown), Volker Kunzmann, Swantje Held, (unknown), Volker Heinemann, Frank Kullmann	2
4	Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial 2022 ·Advances in Therapy ·Michael Dreher, Christian Grohé, Niels‐Ulrik Korbinian Hartmann, Stephan Kanzler, Karin Kraft, (unknown), Michael Doll, (unknown), Stephan Steiner, Jochen Wöhrle, Julia Seeger, (unknown), Jørn Bo Thomsen, Thomas Wittig, Nikolaus Marx, Stephan Eisenmann	1
5	FOLFOX/Bevacizumab +/− Irinotecan in advanced colorectal cancer (AIO) “CHARTA”: Final results and multivariate prognostic factor analysis 2017 ·Annals of Oncology ·Hans‐Joachim Schmoll, Benjamin Garlipp, Christian Junghanß, Malte Leithäuser, Arndt Vogel, (unknown), Ulrich Kaiser, Heinz‐Gert Hoeffkes, Axel Florschütz, Jörn Rüssel, Stephan Kanzler, (unknown), Helmut Forstbauer, Thomas Göhler, Carla Hannig, Bert Hildebrandt, Jörg Steighardt, (unknown), (unknown), Alexander Stein	1
6	Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis 2009 ·Journal of Clinical Gastroenterology ·Marcus A. Wörns, Arndt Weinmann, (unknown), (unknown), Claudia‐Martina Messow, Henning Schulze‐Bergkamen, Andreas Teufel, Marcus Schuchmann, Stephan Kanzler, Christoph Düber, Gerd Otto, Peter R. Galle	121
7	A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction 2009 ·Annals of Oncology ·Markus Moehler, Stephan Kanzler, Michael Geißler, Jochen Raedle, M. Ebert, S Daum, Dimitri Flieger, Thomas Seufferlein, Peter R. Galle, Thomas Hoehler	37
8	A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer 2009 ·BMC Surgery ·André L. Mihaljević, Peter Büchler, Jan Harder, Ralf‐Dieter Hofheinz, Michael Gregor, Stephan Kanzler, Wolff Schmiegel, Volker Heinemann, Esther Endlicher, Günter Klöppel, Thomas Seufferlein, Michael Geißler	13
9	Cetuximab with irinotecan/NA-FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomised multi-centre AIO phase II study 2008 ·mediaTUM (Technical University of Munich) ·Markus Moehler, Tanja Trarbach, T Seufferlein, S. Kubicka, Florian Lordick, Michael Geißler, S Daum, Jochen Wilke, Thomas Höhler, Stephan Kanzler, Peter R. Galle	8
10	Serologic Markers Compared With Liver Biopsy for Monitoring Disease Activity in Autoimmune Hepatitis 2008 ·Journal of Clinical Gastroenterology ·Stefan Lüth, Johannes Herkel, Stephan Kanzler, Christian Frenzel, Peter R. Galle, Hans Peter Dienes, Christoph Schramm, Ansgar W. Lohse	97
11	Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis? 2008 ·The American Journal of Gastroenterology ·Elke Hennes, Ye Htun Oo, Christoph Schramm, U Denzer, Peter Buggisch, Christiane Wiegard, Stephan Kanzler, Marcus Schuchmann, Wulf O. Boecher, Peter R. Galle, David Adams, Ansgar W. Lohse	131
12	In-vivo confocal real-time mini-microscopy in animal models of human inflammatory and neoplastic diseases 2007 ·Endoscopy ·Martin Goetz, Christian Fottner, Esther Schirrmacher, (unknown), (unknown), C. Schneider, David Strand, Stephan Kanzler, (unknown), (unknown), Martin Holtmann, Ralf Schirrmacher, Matthias M. Weber, Martin Anlauf, G. Klöppel, Michael Vieth, Peter R. Galle, Peter Bartenstein, Markus F. Neurath, Ralf Kießlich	58
13	Lebermetastasen kolorektaler Karzinome - wie oft kann man operieren? 2007 ·Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie ·T Junginger, Werner Kneist, F. Dünschede, (unknown), Joachim Seifert, Stephan Kanzler	2
14	Pregnancy in Autoimmune Hepatitis: Outcome and Risk Factors 2006 ·The American Journal of Gastroenterology ·Christoph Schramm, Johannes Herkel, Ulrich Beuers, Stephan Kanzler, Peter R. Galle, Ansgar W. Lohse	152
15	Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics 2002 ·Gut ·(unknown), Johannes Herkel, Albert J. Czaja, (unknown), Stephan Kanzler, Eduardo Luiz Rachid Cançado, Gilda Porta, Mikio Nishioka, Tracey G. Simon, (unknown), W Schlumberger, Peter R. Galle, Ansgar W. Lohse	125
16	Nachweis von SLA/LP-Autoantikörpern bei Patienten mit primär biliärer Zirrhose als Marker für eine sekundäre autoimmune Hepatitis (Overlapsyndrom) 2001 ·DMW - Deutsche Medizinische Wochenschrift ·Stephan Kanzler, Selen Bozkurt, Johannes Herkel, Peter R. Galle, H. P. Dienes, Ansgar W. Lohse	20
17	Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis 2000 ·The Lancet ·(unknown), Silvia Brunner, (unknown), Johannes Herkel, Stephan Kanzler, Karl‐Hermann Meyer zum Büschenfelde, Ansgar W. Lohse	222
18	Apoptosis and the liver 2000 ·Seminars in Cancer Biology ·Stephan Kanzler, Peter R. Galle	125
19	Cutting Edge: Chronic Intestinal Inflammation in STAT-4 Transgenic Mice: Characterization of Disease and Adoptive Transfer by TNF- Plus IFN-γ-Producing CD4+ T Cells That Respond to Bacterial Antigens 1999 ·The Journal of Immunology ·Stefan Wirtz, Susetta Finotto, Stephan Kanzler, Ansgar W. Lohse, Manfred Blessing, Hans A. Lehr, Peter R. Galle, Markus F. Neurath	107
20	Transforming growth factor-β1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity 1998 ·Journal of Hepatology ·(unknown), Wolfgang Herr, Stephan Kanzler, (unknown), Karl‐Hermann Meyer zum Büschenfelde, Hans Peter Dienes, Ansgar W. Lohse	70

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact